Thanks to Stifel 2026 Healthcare Conference for the fireside chat on how we’re leveraging the power of our Glyph platform, the potential of GlyphAllo, BUOY-1 trial design & the importance of proper clinical trial design & execution in #neuropsychiatry. bit.ly/4BM9Qf3

Today at 4pm ET CMO, President of Clinical Development Tony Loebel, Co-Founder & CSO Michael Chen, & CFO Lauren White will participate in a fireside chat at @Stifel 2026 Healthcare Conference. Our team will participate in 1x1 meetings at the conference. bit.ly/4BM9Qf3

1B+ people worldwide live w/ mental illness. For Sofinnova Investments Conversations Series, Co-Founder & CEO Daphne Zohar shared our mission to develop new treatments for #depression & #anxiety & how Glyph is uniquely positioned to overcome challenges in neuropsych drug development.

The Seaport Crew celebrated Halloween w/ a festive gathering & friendly costume competition at our offices! Coming together & bonding as a team helps us better serve those living w/ #neuropsychiatric conditions like #depression & #anxiety. We look forward to more fun gatherings.

Q3: dosed 1st patient in GlyphAgo Ph2a #GAD & sleep disturbance trial & showed that GlyphAllo didn't impair next-morning driving performance in Ph1 driving trial. Next: GlyphAllo BUOY-1 enrollment on track (topline 1H27) & GlyphAgo Ph2/3 initiation (1H27): bit.ly/3Uw6r3e

We’re looking forward to participating in the Stifel 2026 Healthcare Conference in NYC. Management team will present on Nov. 10, at 4pm ET & will participate in 1x1 investor meetings. Press release: bit.ly/3WQPPDW Live & archived webcast: bit.ly/4yJNO9W

Co-Founder & CEO Daphne Zohar & Board Member Denice Torres featured in Boston Globe on the growing number of women leading biotech. “If you want the best people, you’re going to be bringing women to the table.” bit.ly/4iJDidW

The Seaport Crew joined the AFSP's #OutoftheDarkness Walk to support those impacted by suicide. People w/ depression are 20x more likely to die by suicide, reinforcing the importance of advancing new treatments for people w/ depression & other #neuropsychiatric conditions.

Recently the Seaport Crew came together for an afternoon of apple picking, which was a great opportunity to connect as a team. We’re grateful for time together, as it allows us to better serve those living w/ #neuropsychiatric disorders. What a great fall afternoon w/ the Crew!

Seaport Crew has been active: discussions on #neuropsychiatric drug development, IP, trends & scientific presentations. Our team’s leadership in the community - conferences, panels, & industry events, helps us share insights & best practices as we bring new medicines to patients.

First presentation of detailed Phase 1 PK data for GlyphAgo at #ECNP2026, showing dose-dependent increases in agomelatine exposure, no food effect, reinforcing previously reported 6.8x bioavailability & 10x improved PK variability. bit.ly/4yJnEoG

Important milestone: first patient dosed in our Phase 2a trial of GlyphAgo, a Glyphed oral prodrug of agomelatine, in adults w/#GAD & sleep disturbance. Trial is designed to evaluate effects on sleep & anxiety symptoms, w/topline data expected in early ’28 bit.ly/4jI9Cim

To close #SuicidePreventionMonth, we welcomed survivor & speaker Kevin Berthia, who shared his story of hope & resilience. For #WSPD, we wrote letters to those struggling & held a moment of silence. These events inspire our mission to bring new medicines to patients & families

Productive month engaging w/ the investor community: CEO Daphne Zohar at Goldman Sachs Life Science Symposium, plus CSO Michael Chen & CFO Lauren White at TD Cowen's Neuropsychiatry Summit, sharing highlights on our Glyph platform & pipeline. Event replays bit.ly/4jkikT

Upcoming investor conferences: CEO @daphnezohar.bsky.social presents + joins neuro panel at Goldman Sachs Life Sciences Symposium. Mgmt fireside chat at TD Cowen Novel Mechanisms Summit. 1:1 mtgs at H.C. Wainwright Global Investment Conference & Deutsche Bank Healthcare Summit bit.ly/4j2Vwru

Pleased to share positive topline results from our Ph1 driving simulation trial of GlyphAllo. Trial met its primary & key secondary endpoints: no next-morning driving impairment at either dose evaluated, providing addl support for GlyphAllo's differentiated overall profile in MDD bit.ly/4ikqScR

Congrats to Co-Founder & CEO, Daphne Zohar for being named to MassLive's 25, which recognizes the most influential innovators in MA: bit.ly/4xzDku8 This follows her recent recognition by Forbes, highlighting her as a “drug development powerhouse.”

This #SuicidePreventionMonth, we're reminded why our mission to develop potentially life-changing medicines for those w/#anxiety & #depression matters: 1B people globally live w/mental health conditions & those w/depression have a higher likelihood of suicidal ideation & attempts

We're looking forward to upcoming investor conferences: Citi's 2026 Biopharma Back to School Conference (fireside chat w/ Seaport management on 9/9 at 1pm ET) & the 21st Annual Wells Fargo Healthcare Conference. Plus 1x1 meetings at both. Citi webcast: bit.ly/4qFU7ce

The Seaport Crew enjoyed pickleball & paddleball at our summer outing in the Seaport! The team helped each other learn the sports, not so different from our day-to-day work, where we work collaboratively toward our mission of developing new treatments for #depression & #anxiety.

Q2 results: successful IPO, continued pipeline execution w/previously reported positive Ph1 GlyphAgo data. Ahead: GlyphAgo Ph2 in GAD to begin 2H’26, GlyphAllo driving simulation data 2H’26 & Ph2b BUOY-1 topline MDD data 1H’27 & Glyph2BLSD on track bit.ly/3SazpEz

At an internal poster session, employees learned about data presented at recent conferences, including GlyphAllo™ data presented at #ASCP. Sharing findings bridges clinical research & real-world impact, advancing our mission to develop new treatments for #depression & #anxiety.

Our Co-Founder & CEO Daphne Zohar & Board Member Denice Torres were named to the #BLOC100 as Luminaires, recognized for contributions that will shape the future of biopharma. Proud to see their impact recognized, & leadership advancing progress for people living w/mental illness.

CFO Lauren White & CSO Michael Chen, spoke at Goldman Sachs 47th Global Healthcare Conference, highlighting positive Ph1 MAD data for GlyphAgo™ & GlyphAllo™ updates, w/Ph2b BUOY-1 enrollment on track & topline data expected in H1 next year: bit.ly/3S385aU

Listen tomorrow at 8:00AM ET for a fireside chat with CFO, Lauren White, & CSO, Michael Chen, at the Goldman Sachs 47th Annual Global Healthcare Conference. Our team will also participate in 1x1 meetings at the conference. Live & archived webcast: bit.ly/4e956Fn

Today we reported Q1 '26 financial results & business updates. We advanced our clinical programs, including new MAD data from Ph1 trial of GlyphAgo & progress on GlyphAllo w/P2b data expected in 1H '27. Q1 results: bit.ly/4dWcOnj GlyphAgo data: bit.ly/43pTGIj

New positive MAD data from Ph1 POC trial of GlyphAgo confirm favorable safety, tolerability, & PK w/repeat dosing, further reinforcing GlyphAgo’s ability to achieve therapeutic agomelatine exposure at doses projected to avoid liver enzyme elevations: bit.ly/43pTGIj

We're participating in upcoming investor conferences in June, including the Goldman Sachs 47th Annual Global Healthcare Conference & UBS Virtual CNS Day. Seaport will participate in 1x1 meetings at both. Release: bit.ly/4nZNdxb Goldman webcast: bit.ly/4dOaCgb

Proud to join #NAMIWalks this #MentalHealthAwarenessMonth to raise awareness, reduce stigma & support those impacted by mental illness - reinforcing our commitment to developing life-changing treatments for patients w/ #depression, #anxiety & other neuropsychiatric disorders

Our CMO & AFSP board member Dr. Tony Loebel represented Seaport at #Lifesavers26. This #MHM2026 we're reminded suicide is 10th leading cause of death in US - 20x higher risk for those w/ #MDD. Proud to support & reinforce our work advancing #neuropsychiatric treatments.